KLKonstantin Lutz

Konstantin Lutz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantin Lutz has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Krug

    II Medical Department, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany

    3 shared publications
  • Elena Winheim

    Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK

    3 shared publications
  • Lisa Rausch

    Institute for Immunology, Biomedical Center, LMU Munich, Planegg-Martinsried, Germany

    2 shared publications
  • Alexandra Leutbecher

    Affiliations Department of Medicine III, University Hospital, LMU Munich; Munich, Germany, Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich; Munich, Germany

    1 shared publication
  • Andrea Musumeci

    Department of Pharmacology and Therapeutics, Western Gateway Building, University College Cork, T12 XF62 Cork, Ireland

    1 shared publication
  • Anna Reischer

    Affiliations Department of Medicine III, University Hospital, LMU Munich; Munich, Germany, Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich; Munich, Germany

    1 shared publication

Latest Publications

  • CCL17 Promotes Colitis-Associated Tumorigenesis Dependent on the Microbiota

    by Rebecca Metzger, Lis Winter, Nassim Bouznad, Debora Garzetti, Benedikt von Armansperg, Matjaz Rokavec, Konstantin Lutz, Yvonne Schäfer, Sabrina Krebs, Elena Winheim, et al.

    Colorectal cancer is one of the most common cancers and a major cause of mortality. Proinflammatory and antitumor immune responses play critical roles in colitis-associated colon cancer. CCL17, a chemokine of the C-C family and ligand for CCR4, is expressed by intestinal dendritic cells in the steady state and is upregulated during colitis in mouse models and inflammatory bowel disease patients. In this study, we investigated the expression pattern and functional relevance of CCL17 for colitis-associated colon tumor development using CCL17–enhanced GFP-knockin mice. CCL17 was highly expressed by dendritic cells but also upregulated in macrophages and intermediary monocytes in colon tumors induced by exposure to azoxymethane and dextran sodium sulfate. Despite a similar degree of inflammation in the colon, CCL17-deficient mice developed fewer tumors than did CCL17-competent mice. This protective effect was abrogated by cohousing, indicating a dependency on the microbiota. Changes in microbiota diversity and composition were detected in separately housed CCL17-deficient mice, and these mice were more susceptible to azoxymethane-induced early apoptosis in the colon affecting tumor initiation. Immune cell infiltration in colitis-induced colon tumors was not affected by the lack of CCL17. Taken together, our results indicate that CCL17 promotes colitis-associated tumorigenesis by influencing the composition of the intestinal microbiome and reducing apoptosis during tumor initiation.


  • Open Access

    Ly6D+Siglec-H+ precursors contribute to conventional dendritic cells via a Zbtb46+Ly6D+ intermediary stage

    by Konstantin Lutz, Andrea Musumeci, Christopher Sie, Ezgi Dursun, Elena Winheim, Johannes Bagnoli, Christoph Ziegenhain, Lisa Rausch, Volker Bergen, Malte D. Luecken, et al.

    Plasmacytoid and conventional dendritic cells (pDC and cDC) are generated from progenitor cells in the bone marrow and commitment to pDCs or cDC subtypes may occur in earlier and later progenitor stages. Cells within the CD11c+MHCII−/loSiglec-H+CCR9lo DC precursor fraction of the mouse bone marrow generate both pDCs and cDCs. Here we investigate the heterogeneity and commitment of subsets in this compartment by single-cell transcriptomics and high-dimensional flow cytometry combined with cell fate analysis: Within the CD11c+MHCII−/loSiglec-H+CCR9lo DC precursor pool cells expressing high levels of Ly6D and lacking expression of transcription factor Zbtb46 contain CCR9loB220hi immediate pDC precursors and CCR9loB220lo (lo-lo) cells which still generate pDCs and cDCs in vitro and in vivo under steady state conditions. cDC-primed cells within the Ly6DhiZbtb46– lo-lo precursors rapidly upregulate Zbtb46 and pass through a Zbtb46+Ly6D+ intermediate stage before acquiring cDC phenotype after cell division. Type I IFN stimulation limits cDC and promotes pDC output from this precursor fraction by arresting cDC-primed cells in the Zbtb46+Ly6D+ stage preventing their expansion and differentiation into cDCs. Modulation of pDC versus cDC output from precursors by external factors may allow for adaptation of DC subset composition at later differentiation stages.


  • Open Access

    Impaired function and delayed regeneration of dendritic cells in COVID-19

    by Elena Winheim, Linus Rinke, Konstantin Lutz, Anna Reischer, Alexandra Leutbecher, Lina Wolfram, Lisa Rausch, Jan Kranich, Paul R. Wratil, Johanna E. Huber, et al.

    Disease manifestations in COVID-19 range from mild to severe illness associated with a dysregulated innate immune response. Alterations in function and regeneration of dendritic cells (DCs) and monocytes may contribute to immunopathology and influence adaptive immune responses in COVID-19 patients. We analyzed circulating DC and monocyte subsets in 65 hospitalized COVID-19 patients with mild/moderate or severe disease from acute illness to recovery and in healthy controls. Persisting reduction of all DC subpopulations was accompanied by an expansion of proliferating Lineage−HLADR+ cells lacking DC markers. Increased frequency of CD163+ CD14+ cells within the recently discovered DC3 subpopulation in patients with more severe disease was associated with systemic inflammation, activated T follicular helper cells, and antibody-secreting cells. Persistent downregulation of CD86 and upregulation of programmed death-ligand 1 (PD-L1) in conventional DCs (cDC2 and DC3) and classical monocytes associated with a reduced capacity to stimulate naïve CD4+ T cells correlated with disease severity. Long-lasting depletion and functional impairment of DCs and monocytes may have consequences for susceptibility to secondary infections and therapy of COVID-19 patients.